A target trial emulation estimated the risks associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure in early pregnancy. The findings did not indicate substantially increased risk for nonlive… read more.
People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society’s annual meeting… read more.
Eli Lilly and Company, the maker of Zepbound (tirzepatide), announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced significant weight… read more.
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications, according to a… read more.
Novo Nordisk presented post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS clinical trials at the 2026 Scientific Sessions of the American Diabetes Association (ADA), highlighting data regarding the impact… read more.
Chile’s complementary set of policies targeting food products high in fat, salt and sugar plausibly reduces the risk of school age children being overweight or having obesity, finds… read more.
On 21 May 2026, the CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Wegovy. The marketing authorisation… read more.
People who work fewer hours each year appear to have a lower risk of obesity, according to an Australian study presented at the European Congress on Obesity in… read more.
Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research… read more.
Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing… read more.
New research presented at this year’s European Congress on Obesity (ECO 2026) in Istanbul, Turkey, shows that rapid weight loss (RWL) is much more effective than gradual weight… read more.
New research presented at this year’s European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
